After years of advocating for a cure for the rare disease that has limited his mobility, Mark Christman has made his way to Capitol Hill. Christman, a retired attorney and board member of Trib Total ...
Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that can lead to the slow deterioration of muscles, predominantly in the face, shoulder blades, and upper arms. Facioscapulohumeral ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for ...
FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET "This World FSHD Day, we are excited to be joining ...
- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line - FSHD is caused by aberrant activation of ...
Following SOLVE FSHD’s recent acclaimed launch, the organization is pleased to formally announce the appointment of Dr. Eva Chin as the Executive Director. SOLVE FSHD’s Founder, Chip Wilson, has ...
Dyne Therapeutics, Inc. announced promising preclinical data for their therapeutic candidate, DYNE-302, which shows potential for functional improvement in facioscapulohumeral muscular dystrophy (FSHD ...
COLUMBUS, Ohio--(BUSINESS WIRE)--Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced its recognition as one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results